Who is sponsoring NCT05831631?

NCT05831631 is sponsored by Pietro Mortini, MD, Prof..

What drugs are being tested in NCT05831631?

Interventions in NCT05831631: Circulating leukocytes immunophenotype, Tumor sampling.

What condition does NCT05831631 study?

NCT05831631 studies Brain Tumor, Primary, Brain Tumor - Metastatic.

Is NCT05831631 still recruiting?

NCT05831631 is currently recruiting now. Last updated 11 June 2025.

Last reviewed 2025-06-11 · How we verify

NCT05831631

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors

Recruiting now Last updated 11 June 2025

What this trial tests

trial testing Circulating leukocytes immunophenotype in Brain Tumor, Primary in 200 participants. Currently enrolling.

Timeline

1 August 2022

Primary endpoint
31 July 2028

1 August 2029

Quick facts

Lead sponsor	Pietro Mortini, MD, Prof.
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 August 2022
Primary completion	31 July 2028
Estimated completion	1 August 2029
Sites	1 location across Italy

Drugs / interventions tested

Circulating leukocytes immunophenotype
Tumor sampling

Conditions studied

Brain Tumor, Primary — all drugs for Brain Tumor, Primary →
Brain Tumor - Metastatic — all drugs for Brain Tumor - Metastatic →

Sponsor

Pietro Mortini, MD, Prof.

Who can join

18 and older, any sex, with Brain Tumor, Primary or Brain Tumor - Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome. Participants will be subjected to blood sampling before surgery and for 12 months of follow-up. Additional sampling and analysis will be performed on tumor samples.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Brain Tumor, Primary

Currently open trials in the same condition.

NCT06185686 — Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients · recruiting
NCT06282562 — FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients · NA · recruiting
NCT04427384 — Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) · recruiting
NCT05775458 — Glutamate Excitotoxicity and Its Role in Glioblastoma Biology · recruiting
NCT05254197 — SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05831631 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pietro Mortini, MD, Prof.
Last refreshed: 11 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05831631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing